Economic Impact Model of Breast Cancer Treatment at Early Stages in the Mexican Public Health Care Sector

Abstract

2039 to EUR 9346, depending on care required, more costly than SREs without hospitalization (n= 165). These SREs had median costs of EUR 200 to EUR 1912, depending on care required. ConClusions: The impact of SREs on total costs could justify policy aimed at actively preventing SREs, e.g. with radionuclide therapy, possibly resulting in better quality of life and cost-reduction. Treatment of prostate cancer with bone metastases is not very costly compared to lung-and breast cancer with similar metastases. However, novel therapeutic options may dramatically increase treatment costs in the near future and proper head-to-head cost-effectiveness studies of all treatment modalities are therefore necessary. PCN72objeCtives: To assess the intramural resource use and associated costs of treating patients with prostate cancer, metastatic to the bone, focusing on Skeletal Related Events (SREs). Secondary, to quantify the impact of SREs and different treatment strategies on total costs. Methods: A retrospective bottom-up cost of illness study performed at a large regional teaching hospital in the Netherlands. Results: A total of 136 patients were included, follow-up started at diagnosis of bone metastases and stopped at death. The mean total costs were EUR 17.931 per patient (median EUR 14.039), inpatient days were the most costly category at a mean of EUR 5955 (median EUR 3995). SREs that required hospitalization (n= 53) were, at median costs of EUR